Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.
ASJC Scopus subject areas